Integrated Proteomic and scRNA‐Seq Analysis Reveals Pyroptosis‐Related Subtypes in Lung Adenocarcinoma
Open Access
- 5 July 2026
- journal article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 20 (7) , e70210
Abstract
Background: Pyroptosis is a recently identified form of programmed cell death that plays an important role in cancer initiation and progression. However, the function of pyroptosis in lung adenocarcinoma (LUAD) remains unclear. The study integrated proteomic and single‐cell RNA sequence (scRNA‐seq) data to investigate the potential role of pyroptosis‐related proteins (PRPs) in the tumor microenvironment (TME) and their associations with tumor immunity, prognosis, and therapeutic response. Methods: A comprehensive proteomic analysis was conducted on 103 lung adenocarcinoma patients. We integrated scRNA‐seq data with bioinformatics analyses to evaluate prognostic and immunological characteristics. Unsupervised clustering based on the PRP expression identified three subtypes. We then used gene set enrichment analysis (GSEA) to assess biological functions. We applied TME and CIBERSORT algorithms to analyze immune cell infiltration. Next, we performed functional enrichment, immune infiltration, and cell–cell communication analyses using scRNA‐seq data grouped according to the proteomic subtypes. We constructed a PRP‐related prognostic signature using least absolute shrinkage and selection operator (LASSO)‐Cox regression analysis. Finally, we validated the expression and functional significance of selected proteins by immunohistochemistry, Western blotting, quantitative PCR, and in vitro loss‐of‐function assays. Results: We identified multiple PRPs that correlated with clinicopathologic characteristics, patient prognosis, and immune infiltration patterns in the TME. We further identified three distinct molecular subtypes, including lipid metabolism, signaling transduction, and immune activation. Among these subtypes, the lipid metabolism subtype showed the best prognosis. ScRNA‐seq analysis further supported the immune characteristics of three subtypes and revealed distinct cellular interaction networks and ligand‐receptor pairs. We also established and validated a PRP‐related prognostic score that effectively predicted overall survival in patients with LUAD. In addition, the PRP score was significantly associated with tumor immune status and sensitivity to chemotherapeutic agents. Conclusion: Our integrated analysis of proteomic and scRNA‐seq data demonstrated that PRPs are closely associated with the tumor‐immune‐stromal microenvironment, clinicopathological features, and prognosis in LUAD. These findings improve our understanding of the biological roles of PRPs in LUAD and may provide new strategies for prognostic evaluation and immunotherapy development.Keywords
Funding Information
- National Natural Science Foundation of China (82570107)
- National Natural Science Foundation of China (82130001)
- National Natural Science Foundation of China (82500110)
- National Natural Science Foundation of China (82203517)
- National Natural Science Foundation of China (82200089)
- National Natural Science Foundation of China (82400103)
- Zhongshan Hospital (ZY2024‐001)
- Zhongshan Hospital (ZSLCYJ202319)
- China Postdoctoral Science Foundation (2024M750545)
- China Postdoctoral Science Foundation (2024T170162)
This publication has 29 references indexed in Scilit:
- Inflammatory Caspases Drive Pyroptosis in Acute Lung InjuryFrontiers in Pharmacology, 2021
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Lung cancerNature, 2020
- Lipid metabolism gene-wide profile and survival signature of lung adenocarcinomaLipids in Health and Disease, 2020
- NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsAnnals of Oncology, 2020
- Integrative Proteomic Characterization of Human Lung AdenocarcinomaCell, 2020
- A bioorthogonal system reveals antitumour immune function of pyroptosisNature, 2020
- Pyroptosis: A new frontier in cancerBiomedicine & Pharmacotherapy, 2020
- Transcription Factor p53 Suppresses Tumor Growth by Prompting Pyroptosis in Non-Small-Cell Lung CancerOxidative Medicine and Cellular Longevity, 2019
- Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activationApoptosis, 2019